Download Image
    
Share
  
Post
LSALT peptide for COVID-19
1 study with 61 patients
Hospital Icon Control
Hospital Icon LSALT peptide Serious Outcome Risk
No significant improvements are seen in meta-analysis to date.
COVID-19 LSALT peptide studies. May 2026. c19early.org
0 0.5 1 1.5+ All studies -407% Mortality -407% Hospitalization -7% RCTs -407% Late -407% FavorsLSALT peptide Favorscontrol
May 18
2024
 Fowler et al., NCT04330690 A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)
Estimated 580 patient LSALT peptide late treatment RCT with results not reported over 2 years after estimated completion.
Mar 15
2024
 Somayaji et al., BMJ Open, doi:10.1136/bmjopen-2023-076142 Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19)
407% higher mortality (p=0.24) and 7% longer hospitalization (p=0.65). RCT 61 hospitalised moderate/severe COVID-19 patients showing no significant difference in clinical outcomes with intravenous LSALT peptide treatment.